| JXSL1800045 | Durvalumab | durvalumab | Injection | Biological Products | Import Drug Application | 2018-10-29 | | Medimmune LLC | In Review | 2018-10-27 | view |
| JXSL2500017 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products(2.2) | Import Drug Application | 2025-01-24 | | Medimmune LLC;Astrazeneca Investment (China) Co Ltd | | | view |
| JXSB2200046 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products | Supplementary Application | 2022-04-24 | | Medimmune LLC;Catalent Indiana LLC | | | view |
| JXSB2000041 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products | Supplementary Application | 2020-12-03 | | Medimmune LLC;Catalent Indiana LLC | In Review | 2020-12-03 | view |
| JXSL1900047 | Durvalumab | durvalumab | Injection | Biological Products | Import Drug Application | 2019-05-15 | | Medimmune LLC | In Review | 2019-05-14 | view |
| JXSS2500027 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products(3.1) | Import Drug Application | 2025-03-22 | | AstraZeneca AB;Catalent Indiana LLC;Astrazeneca Investment (China) Co Ltd;Astrazeneca Uk Ltd | | | view |
| JYSB2300121 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products | Supplementary Application | 2023-07-14 | | AstraZeneca AB;Catalent Indiana LLC;Astrazeneca Uk Ltd | | | view |
| JXSB2101044 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products | Supplementary Application | 2021-08-09 | | Medimmune LLC;Catalent Indiana LLC | | | view |
| JXSL2000047 | Durvalumab | durvalumab | Injection | Biological Products | Import Drug Application | 2020-05-18 | | Medimmune LLC | In Review | 2020-05-16 | view |
| JXSS2500037 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products(3.1) | Import Drug Application | 2025-03-28 | | AstraZeneca AB;Catalent Indiana LLC;Astrazeneca Investment (China) Co Ltd;Astrazeneca Uk Ltd | | | view |
| JXSS2400066 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products(2.2) | Import Drug Application | 2024-08-16 | | Catalent Indiana LLC;Astrazeneca Investment (China) Co Ltd;Astrazeneca Uk Ltd | | | view |
| JYSB2200176 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products | Supplementary Application | 2022-09-10 | | Catalent Indiana LLC;Astrazeneca Uk Ltd | | | view |
| JXSB2000012 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products(2.2) | Supplementary Application | 2020-09-10 | | Medimmune LLC;Catalent Indiana LLC | In Review | 2020-09-09 | view |
| JXSL1800077 | Durvalumab | durvalumab | Injection | Biological Products | Import Drug Application | 2019-01-09 | | Medimmune LLC | In Review | 2019-01-08 | view |
| JXSS2500014 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products(3.1) | Import Drug Application | 2025-02-21 | | AstraZeneca AB;Catalent Indiana LLC;Astrazeneca Investment (China) Co Ltd;Astrazeneca Uk Ltd | | | view |
| JXSS2300025 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products(3.1) | Import Drug Application | 2023-03-11 | | Catalent Indiana LLC;Astrazeneca Investment (China) Co Ltd;Astrazeneca Uk Ltd | | | view |
| JYSB2100016 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products | Supplementary Application | 2021-01-12 | | Catalent Indiana LLC;Astrazeneca Uk Ltd | Filed | 2021-01-22 | view |
| JXSL2000026 | Durvalumab | durvalumab | Injection | Biological Products | Import Drug Application | 2020-03-06 | | Medimmune LLC | In Review | 2020-03-05 | view |
| JXSS2300077 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products(2.2) | Import Drug Application | 2023-09-08 | | Catalent Indiana LLC;Astrazeneca Investment (China) Co Ltd;Astrazeneca Uk Ltd | | | view |
| JYSB2200078 | 度伐利尤单抗注射液 | durvalumab | Injection | Biological Products | Supplementary Application | 2022-04-24 | | Catalent Indiana LLC;Astrazeneca Uk Ltd | | | view |
